Durata Therapeutics Inc. (DRTX) announced Monday morning that it agreed to be acquired by Actavis plc (ACT) for $23.00 per share in cash, or approximately $675 million.
Durata Therapeutics gapped open dramatically higher Monday, but moved in a narrow range throughout the session. Shares finished with a gain of 10.36 at $24.24 on the highest volume of the year. The stock jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News